Eisai Enters Agreement With Minophagen; Gains Asian Access to Liver Disease Products
This article was originally published in PharmAsia News
Executive Summary
Under the shadow of Eisai's recent, massive "Dramatic Leap Plan" acquisitions, the company acquires the Asian development and marketing rights for Minophagen Pharmaceutical's Stronger Neo-Minophagen C and Glycyron products
You may also be interested in...
Asia Hep B Trials Could Preview U.S. Studies - Analyst
As clinical development programs mature in Asia, U.S. investors and analysts may increasingly look to Asian clinical trials to get a preview of a compound's potential success in U.S. markets
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).